The new ministerial guidance letter (‘LOM’) intended to guide the Economic Committee for Health Products (‘CEPS’) on the pricing strategy for pharmaceutical products and medical devices has been signed and published on 5 May...more
Au travers de diverses évolutions récentes, la situation économique des entreprises pharmaceutiques opérant en France devient progressivement plus contraignante. ...more
Through various recent evolutions, the economic situation of the pharmaceutical companies operating in France become increasingly challenging. Various evolutions have recently occur in France: The Ministry of Health is...more
We were pleased to welcome industry leaders to our Life Sciences and Health Care Horizons event in Zurich, where co-head of Hogan Lovells Life Sciences and Health Care sector Jane Summerfield, and partners Melissa K. Bianchi,...more
Le PLFSS 2024 sanctionne les fabricants de dispositifs médicaux "polluants" Le Gouvernement poursuit sa volonté d’opérer la transition écologique à travers deux mesures introduites à l’article 29 du PLFSS 2024 dont l’une va...more
Companies marketing 'polluting' medical devices will be penalised under the French Social Security Financing Bill for 2024. The French Government continues its desire to implement ecological transition through measures...more
On 31 December 2020, the French National Authority for Health (Haute Autorité de Santé - “HAS”), in charge of health technology assessment of health care products before access to reimbursement by the public health insurance...more
Faced with the unprecedented sanitary crisis caused by the COVID-19 epidemic, Article 4 of emergency law n° 2020-290 of 23 March 2020 has created the new legal concept of a health state of emergency and has invoked this...more
Since 2017, the French financial regulation applicable to medical devices is gradually moving closer to the regulation governing pharmaceutical products.
...more
On June 27 the third edition of our new global series, Life Sciences and Health Care Horizons, took place in Paris with discussions focused on the pricing and financial regulation of health products after the latest reforms....more